Early and sustained improvement with vilazodone in adult patients with major depressive disorder: Post hoc analyses of two phase III trials

Current Medical Research and Opinion

Volumn 30, Issue 2, 2014, Pages 263-270

  Jain, Rakesh ^a   Chen, Dalei ^b   Edwards, John ^b   Mathews, Maju ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Major depressive disorder; Selective serotonin reuptake inhibitors; Serotonin 5 HT1A receptor agonists; Vilazodone

Indexed keywords

PLACEBO; VILAZODONE; ANTIDEPRESSANT AGENT; BENZOFURAN DERIVATIVE; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; SEROTONIN 1 AGONIST; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DSM-IV-TR; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIDDLE AGED; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; YOUNG ADULT; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSIVE DISORDER, MAJOR; DOUBLE BLIND PROCEDURE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY;

ADULT; ANTIDEPRESSIVE AGENTS; BENZOFURANS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PIPERAZINES; PLACEBOS; RETROSPECTIVE STUDIES; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84893272144     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.855188     Document Type: Conference Paper

References (31)

1. Thase ME. Update on partial response in depression. J Clin Psychiatry 2009;70(Suppl 6):4-9
2. Katz MM, Frazer A, Bowden CL. Delay hypothesis of onset of antidepressant action. Br J Psychiatry 2006;188:586-7
3. Rojo JE, Gibert K, Cobo J, et al. Onset of antidepressant action: A pharmacological question? Hum Psychopharmacol 2005;20:425-33
4. Taylor MJ. Rapid onset of true antidepressant action. Curr Psychiatry Rep 2007;9:475-9
5. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: Systematic review and meta-Analysis. Arch Gen Psychiatry 2006;63:1217-23
6. Wade A, Friis Andersen H. The onset of effect for escitalopram and its relevance for the clinical management of depression. Curr Med Res Opin 2006;22:2101-10
7. Papakostas GI, Perlis RH, Scalia MJ, et al. A meta-Analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol 2006;26: 56-60
8. Montgomery SA, Moller HJ. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol 2009;24:111-18
9. Papakostas GI, Perlis RH, Scalia MJ, et al. A meta-Analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol 2006;26:56-60
10. Szegedi A, Jansen WT, van Willigenburg AP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: A meta-Analysis including 6562 patients. J Clin Psychiatry 2009;70:344-53
11. Lam RW. Onset, time course and trajectories of improvement with antidepressants. Eur Neuropsychopharmacol 2012;22(Suppl 3):S492-8
12. Dawson LA, Watson JM. Vilazodone: A 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci Ther 2009;15:107-17
13. Hughes ZA, Starr KR, Langmead CJ, et al. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol 2005;510:49-57
14. Khan A, Cutler AJ, Kajdasz DK, et al. A randomized, double-blind, placebocontrolled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry 2011;72:441-7
15. Rickels K, Athanasiou M, Robinson DS, et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:326-33
16. Robinson DS, Kajdasz DK, Gallipoli S, et al. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol 2011;31:643-6
17. Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry 2008;69(Suppl E1):4-7
18. Portella MJ, de Diego-Adelino J, Ballesteros J, et al. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-Analysis of pindolol in nonresistant depression. J Clin Psychiatry 2011;72:962-9
19. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 2003;53:193-203
20. Montgomery SA,Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
21. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association, 2000
22. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
23. Sussman N. Depression and painful physical symptoms. Primary care companion to the Journal of Clinical Psychiatry 2003;5(Suppl 7):19-26
24. Thase ME. The small specific effects of antidepressants in clinical trials: What do they mean to psychiatrists? Curr Psychiatry Rep 2011;13:476-82
25. Papakostas GI, Petersen T, Denninger JW, et al. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol 2004;24:507-11
26. Stassen HH, Angst J, Hell D, et al. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry 2007;68:1195-205
27. Baldwin DS, Stein DJ, Dolberg OT, et al. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol 2009; 24:269-75
28. Kasper S, Pail G. Milnacipran: A unique antidepressant? Neuropsychiatr Dis Treat 2010;6:23-31
29. Valuck RJ, Orton HD, Libby AM. Antidepressant discontinuation and risk of suicide attempt: A retrospective, nested case-control study. J Clin Psychiatry 2009;70:1069-77
30. Kornstein SG, Li D, Mao Y, et al. Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: Integrative analysis of four double-blind, randomized clinical trials. CNS Spectrums 2009;14:326-33
31. Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebocontrolled studies in major depressive disorder. Int Clin Psychopharmacoly 2004;19:149-55